Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
The $13 Million Company Teaching the Immune System to Hunt Cancer
09:00am, Friday, 29'th May 2026
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
04:01pm, Tuesday, 12'th May 2026
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
11:30am, Friday, 17'th Apr 2026
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
04:01pm, Wednesday, 15'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au
Nkarta to Participate in Needham Virtual Healthcare Conference
07:00am, Thursday, 09'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts
02:20am, Monday, 06'th Apr 2026
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
04:01pm, Wednesday, 25'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
01:14am, Tuesday, 03'rd Mar 2026
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two c
Nkarta to Participate in March Investor Conferences
08:00am, Friday, 27'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat
Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc.
03:50am, Saturday, 13'th Dec 2025
AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% during the second quarter, according to the company in its most recent Form 13F filing with the Secur
Nkarta to Participate in Evercore Healthcare Conference
07:09am, Tuesday, 02'nd Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason
08:28am, Saturday, 22'nd Nov 2025
Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early pr
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
04:01pm, Monday, 10'th Nov 2025
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamid
Nkarta to Participate in November Investor Conferences
01:14pm, Thursday, 30'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
10:07am, Wednesday, 22'nd Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat
